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Abstract
 
A major pathway by which growth factors, such as platelet-derived growth factor (PDGF),
regulate cell proliferation is via the receptor tyrosine kinase/Ras/mitogen-activated protein
kinase (MAPK) signaling cascade. The output of this pathway is subjected to tight regulation
 
of both positive and negative regulators. One such regulator is p62
 
dok
 
, the prototype of a
newly identified family of adaptor proteins. We recently provided evidence, through the use
of p62
 
dok
 
-deficient cells, that p62
 
dok
 
 acts as a negative regulator of growth factor–induced cell
proliferation and the Ras/MAPK pathway. We show here that reintroduction of p62
 
dok
 
 into
 
p62
 
dok
 

 
/
 

 
 cells can suppress the increased cell proliferation and prolonged MAPK activity seen
in these cells, and that plasma membrane recruitment of p62
 
dok
 
 is essential for its function. We
also show that the PDGF-triggered plasma membrane translocation of p62
 
dok
 
 requires activa-
tion of phosphoinositide 3-kinase (PI3-kinase) and binding of its pleckstrin homology (PH)
 
domain to 3
 

 
-phosphorylated phosphoinositides. Furthermore, we demonstrate that p62
 
dok
 
 can
exert its negative effect on the PDGFR/MAPK pathway independently of its ability to associ-
ate with RasGAP and Nck. We conclude that p62
 
dok
 
 functions as a negative regulator of the
PDGFR/Ras/MAPK signaling pathway through a mechanism involving PI3-kinase–depen-
dent recruitment of p62
 
dok
 
 to the plasma membrane.
 
Key words: growth factors • cell proliferation • membrane lipids • signal transduction • 
protein-serine-threonine kinase
 
Introduction
 
The Dok proteins (downstream of tyrosine kinases) are a
newly identified family of adaptor proteins phosphorylated
by a wide range of protein tyrosine kinases (PTKs). The
family includes the prototype family member, p62
 
dok
 
,
which was originally identified as a tyrosine-phosphory-
lated 62-kD protein associated with p120RasGAP (1, 2), a
negative regulator of Ras (3). p62
 
dok
 
 is phosphorylated
upon activation of receptor tyrosine kinases (RTKs)
 
*
 
 (in-
 
cluding the epidermal growth factor receptor, platelet-
derived growth factor receptor, and insulin receptor), anti-
gen receptors (such as Fc
 

 
RIIB), and nonreceptor tyrosine
kinases (including v-Src, v-Abl, and the p210
 
bcr-abl
 
 fusion
oncoprotein) (1, 4–9). While the sequence of p62
 
dok
 
 sug-
gested that the protein may serve as a docking protein (1,
2), recent studies have shed light on its function as a nega-
tive regulator of cell proliferation and the Ras/mitogen-
activated protein kinase (MAPK) signaling pathway.
A major contribution towards deciphering the function
of p62
 
dok
 
 came from studies that described the properties of
p62
 
dok
 

 
/
 

 
–derived cells in response to various stimuli. We
recently demonstrated that cells of multiple origins, such as
bone marrow cells, thymocytes, and mouse embryo fibro-
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Abbreviations used in this paper:
 
 aa, amino acid(s); MAPK, mitogen-acti-
vated protein kinase; MEF, mouse embryo fibroblast; MLV, multilamellar
vesicle; PC, phosphatidylcholine; PDGFR, platelet-derived growth factor
receptor; PH, pleckstrin homology; PS, phosphatidylserine; PTB, phos-
photyrosine binding; RT, room temperature; RTK, receptor tyrosine ki-
nase; SHIP1, Src homology 2 domain–containing inositol 5-phosphatase;
WT, wild-type.
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dok
 
blasts (MEFs), isolated from p62
 
dok
 
 knockout mice, showed
a higher degree of proliferation upon growth factor stimu-
lation than those from wild-type (WT) mice. Moreover,
we observed sustained MAPK activation and prolonged
levels of activated, GTP-bound Ras after growth factor re-
moval in p62
 
dok
 

 
/
 

 
 MEF cells (10). In addition, using
splenic B cells derived from p62
 
dok
 

 
/
 

 
 mice, Yamanashi et
al. provided consistent evidence for a negative role of
p62
 
dok
 
 in antigen receptor–mediated signaling through sup-
pression of MAPK activity and cell proliferation (7). Taken
together, these studies suggest that the negative effect of
p62
 
dok
 
 on cell proliferation is at least in part due to nega-
tively influencing the Ras/MAPK pathway.
As a docking molecule, p62
 
dok
 
 harbors several character-
istic motifs and domains. At its N terminus, p62
 
dok
 
 contains
a pleckstrin homology (PH) domain followed by a phos-
photyrosine-binding (PTB) domain, while the COOH-
terminal tail of p62
 
dok
 
 harbors 10 potential tyrosine phos-
phorylation sites and 7 PxxP motifs, which may serve as
docking sites for SH3 domains (1, 2, 11, 12). The PTB do-
main of p62
 
dok
 
 was recently found to be a functional PTB
module and is involved in its association with Src homol-
ogy 2 (SH2) domain–containing inositol 5-phosphatase
(SHIP1) (8, 13), as well as in the homodimerization of
p62
 
dok
 
 through its interaction with a phospho-tyrosine resi-
due (Tyr 146) (14). Interestingly, mutations in the PTB
domain that block homodimerization significantly reduce
the ability of p62
 
dok
 
 to inhibit v-Src–induced transforma-
tion (14). Phosphorylation of the multiple tyrosine residues
at the COOH terminus of p62
 
dok
 
 have been shown to cre-
ate docking sites for proteins containing SH2 domains, in-
cluding Nck, RasGAP, and Csk (1, 4, 8, 13, 15, 16, 17).
Studies on the more recently identified Dok family mem-
bers, p56
 
dok-2
 
 (or DokR and IL-4R interacting protein
[FRIP]) and Dok3 (or DokL) (18–22), using overexpression
experiments, are consistent with a role for the Dok proteins
as negative regulators of cell proliferation and MAPK activa-
tion induced by different stimuli (20–24). In addition to
containing the motifs and domains featured above for p62
 
dok
 
,
p56
 
dok-2
 
 has been demonstrated to associate with RasGAP
and Nck upon tyrosine phosphorylation (18, 19, 25), and
Dok3 with SHIP1 and Csk, but not RasGAP (21, 22).
Despite the identification of the various protein–protein
interactions mentioned above, the mechanism by which
p62
 
dok
 
 negatively interferes with cell proliferation and the
Ras/MAPK pathway remains unclear. In particular, the
role of the PH domain of p62
 
dok
 
 remains to be clarified as
to whether it affects the subcellular localization of p62
 
dok
 
 in
response to growth factors, and in turn influences its bio-
logical functions. Furthermore, the functional relevance of
the association of p62
 
dok
 
 with RasGAP is unclear. It is
tempting to speculate that upon growth factor stimulation,
p62
 
dok
 
 brings RasGAP into the vicinity of Ras in order to
attenuate Ras activation, resulting in a decrease in MAPK
activity and cell proliferation. Tamir et al. have provided
evidence in favor of this model. They overexpressed chi-
meric receptors containing the extracellular and transmem-
brane domains of the Fc
 

 
RIIB fused to the COOH-termi-
 
nal portion of p62
 
dok
 
, which includes the RasGAP-binding
region. Upon BCR/Fc
 

 
RIIB coaggregation, the chimera
was able to recruit RasGAP and suppress MAPK activation
(8). However, in contrast to the above model, overexpres-
sion of either a p56
 
dok-2
 
 mutant deficient in RasGAP bind-
ing, or Dok3, which is unable to bind to RasGAP, still re-
sulted in the downregulation of MAPK activity induced by
EGFR or v-abl, respectively (22, 23). Although these dis-
crepancies might be caused by differences between DOK
family members, stimuli, or cell types, the function of the
RasGAP/p62
 
dok
 
 complex requires further elucidation using
a p62
 
dok
 
 mutant deficient in RasGAP binding.
In this study, we first establish the role of p62
 
dok
 
 as a neg-
ative regulator of the PDGFR/Ras/MAPK pathway by
performing rescue experiments and overexpression studies.
Subsequently, we further investigate the mechanism by
which p62
 
dok
 
 exerts its effects. We demonstrate that in re-
sponse to PDGF, the PH domain of p62
 
dok
 
 mediates the re-
cruitment of the protein to the plasma membrane in a
phosphoinositide 3-kinase (PI3-kinase) activity-dependent
manner, and that this translocation is important for the ty-
rosine phosphorylation of p62
 
dok
 
, as well as for its function
as a negative regulator of the PDGFR/MAPK pathway.
We also provide evidence suggesting that the mechanism
by which p62
 
dok
 
 negatively influences PDGF-triggered
MAPK activity is not dependent on the recruitment of
RasGAP to the membrane, or displacement of Nck, a
known positive regulator of the Ras/MAPK pathway.
 
Materials and Methods
 
Plasmid Constructs and Abs.
 
Retroviral pMaRxIV-p62
 
dok
 
wild-type (WT) and p62
 
dok
 

 
PH constructs, used to generate Rat1
stable cell lines, were obtained by cloning full-length and amino
acids (aa) 121–481 of human p62
 
dok
 
 into the EcoRI site and
EcoRI/XhoI sites of pMaRxIV vector (gift from G. Hannon,
Cold Spring Harbor Laboratory). GFP-expressing full-length
p62
 
dok
 
, p62
 
dok
 
PH, and p62
 
dok
 

 
PH constructs were generated by
cloning PCR generated fragments of p62
 
dok
 
 full-length, aa 1–120
and aa 121–481 into the EcoRI/SalI sites of pEGFP-N
 
3
 
 (CLON-
TECH Laboratories, Inc.). The His-tagged p62
 
dok
 
 bacterial expres-
sion constructs were obtained by cloning PCR generated p62
 
dok
 
fragments into the KpnI/SalI sites of pQE30 (QIAGEN). The ret-
roviral constructs pBabePuro-p62
 
dok
 
WT, p62
 
dok
 
RasGAP binding
deficient mutant (p62
 
dok
 
GBD), used in the rescue experiments,
were constructed by cloning full-length cDNA and a cDNA con-
taining Tyr
 
→
 
Phe mutations at aa 296, 315, 362, 398, and 409 into
the EcoRI site of pBabePuro, respectively. The p62
 
dok
 

 
PH con-
struct was generated by cloning aa 121–481 of p62
 
dok
 
 into
EcoRI/SalI sites of pBabePuro (26). myc-tagged p62
 
dok
 
WT and
p62
 
dok
 
GBD were obtained by cloning the corresponding cDNAs
into the EcoRI/XhoI sites of pcDNA3.1/myc-His vector (Invit-
rogen). Polyclonal Abs against p62
 
dok
 
 were generated against pep-
tides derived from a 15-aa sequence in the COOH terminus (1)
and from a 14-aa sequence (LQSQFFGTKRWRKT) in the N-ter-
minal region of human p62
 
dok
 
. Monoclonal Abs were generated
against GST-human p62
 
dok
 

 
PH purified protein. These Abs do
recognize rat and mouse p62
 
dok
 
, but with much lower affinity.
 
Cell Culture, Transfection, and Infection.
 
Rat1 cells, WT MEF
cells, and p62
 
dok
 

 
/
 

 
 MEF cells were maintained in DMEM con-
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taining 10% fetal bovine serum. Retroviral gene transfer was per-
formed as described (27). Infected cell populations were selected
by culturing in the media described above containing hygromy-
cin (100 
 

 
g/ml) for 5 d or puromycin (2.5 
 

 
g/ml) for 3 d. For
transient transfections, Fugene 6 (Roche Molecular Biochemi-
cals) was used according to the manufacturer’s recommendations.
 
Cell Fractionation.
 
Cells were serum starved for 16 h and stim-
ulated with PDGF (50 ng/ml) for 15 min. When PI3-kinase in-
hibitors were used, cells were treated with wortmannin (25 nM) or
LY292004 (25 
 

 
M) for 5 min, and subsequently stimulated with
PDGF. Cells were then homogenized in detergent-free buffer (10
mM Tris-HCl, pH 7.5, 2 mM MgCl
 
2
 
, 0.2 M sucrose, 0.5 mM
EDTA), and centrifuged at 1,000 
 
g
 
 for 10 min at 4
 

 
C. The pellets
were homogenized again and centrifuged as above. The superna-
tants from both steps were pooled and centrifuged at 100,000 
 
g
 
 for
40 min to give the S100 (cytosolic) fraction. The corresponding
pellet was homogenized in 6 mM Tris-HCl, pH 8.0, 1 mM
EDTA, and centrifuged another 40 min at 100,000 
 
g
 
. The pellet
was homogenized again, and resuspended in 20 mM Tris-HCl,
pH 7.5, 1 mM EDTA. This fraction represents the P100 (mem-
brane) fraction. All buffers contained protease and phosphatase in-
hibitors. An equal amount of protein from each fraction was sub-
jected to immunoprecipitation and Western blot analyses.
 
Purification of Full-Length p62
 
dok
 
, p62
 
dok
 

 
PH, and p62
 
dok
 
PH His-
tagged Proteins.
 
The bacterially expressed His-tagged p62
 
dok
 
,
p62
 
dok
 
PH, and p62
 
dok
 

 
PH proteins were purified on Ni
 
2
 

 
 af-
finity columns according to the manufacturer’s instructions
(QIAGEN). The protein samples were dialyzed against 50 mM
Hepes, pH 8.0, 150 mM NaCl, and stored at 
 

 
20
 

 
C until use.
 
Lipid Binding Assays.
 
Multilamellar vesicles (MLVs) were
used to analyze lipid-binding according to published procedures
(28, 29). Synthetic phospholipids were obtained from Avanti Polar
Lipids and from Matreya. To prepare MLVs, lipids in chloroform/
methanol/water were mixed at the desired ratios and evaporated
to dryness at room temperature (RT) in a Rotavapor (Buechi).
The lipid film was further desiccated under high vacuum for 2 h in
the dark and rehydrated at a concentration of 2 mg/ml in buffer A
(10 mM morpholino propane sulfonic acid [MOPS], pH 7.4, 0.1
mM EGTA, 100 mM NaCl, 0.01% Triton X-100) by intermittent
gentle shaking over 20 min at RT. MLVs were collected by cen-
trifugation at 15,000 
 
g for 10 min at 4C, and resuspended in the
original volume of fresh buffer A. p62dok full-length, p62dokPH,
and p62dokPH His-tagged proteins were diluted to 100 ng/l in
buffer A (supplemented with protease inhibitors) and centrifuged
at 15,000 g for 10 min at 4C. The supernatant was used as a pro-
tein stock solution. For the binding assay, serial dilutions of MLVs
were added to 0.5 g of protein in a total volume of 100 l of
buffer A, and the reactions were incubated at RT for 30 min.
Subsequently, free and lipid-bound proteins were separated by
centrifugation at 15,000 g for 10 min at 4C. The supernatant was
immediately removed and supplemented with 25 l 5	 SDS
loading buffer, whereas the pellet was resuspended in 125 l 1	
SDS loading buffer. The samples were boiled for 3 min at 95C
and 20 l of each sample was loaded on polyacrylamide gels,
which were then processed for Western blotting.
Immunofluorescence Studies. 5 	 104 Rat1 cells were plated on
30-mm round glass coverslips, transfected, and serum starved for
20 h. The coverslips were placed into a chamber that was
mounted on a heated stage and kept at 36.5C. The cells were in-
cubated in serum-free DMEM, and treated with indicated stimuli
and PI3-kinase inhibitors. Images were taken and processed using
an inverted ZEISS confocal microscope under 100	 oil immer-
sion objective and LSM50 software.
MAPK Assay. Cells were lysed in lysis buffer (50 mM Tris-
HCl, pH 7.5, 100 mM NaCl, 1% Triton, 5 mM EDTA, 40 mM

-glycerophosphate, 50 mM NaF, 100 M PMSF, 1 g/ml leu-
peptin, 1 g/ml aprotinin, 1 mM sodium orthovanadate). Equal
amounts of each sample were resolved on 12% SDS-PAGE gels,
transferred to nitrocellulose membranes, and immunoblotted
with phospho-specific p44/p42 MAPK Ab (New England Bio-
Labs, Inc.) to measure the activation status of MAPK. To verify
equal loading, membranes were blotted with p42 MAPK Ab
(Santa Cruz Biotechnology, Inc.). Immunoblots were visualized
using enhanced chemiluminescence detection reagents (ECL;
Amersham Pharmacia Biotech).
Cell Proliferation Assay. Cell proliferation was assessed by
[3H]thymidine incorporation assays. WT and p62dok/ MEF
cells, infected with p62dok WT or empty vector (5 	 104 cells/
well in 12-well plates), were serum starved for 24 h, and then
stimulated by adding 50 ng/ml of PDGF. 12 h later, the cells
were pulsed with 5 Ci/ml [methyl-3H]thymidine; and after an-
other 3 h, the cells were washed, trypsinized, and transferred to
glass fiber filters followed by scintillation counting.
Results
Suppression of Increased Cell Proliferation and MAPK Ac-
tivity by Reintroducing p62dok into p62dok-deficient Cells.
Recently, we inactivated p62dok by homologous recombi-
nation and observed that p62dok/ cells derived from mul-
tiple origins exhibited a higher proliferation rate in response
to different growth factors when compared with their cor-
responding WT cells. Moreover, we found that inactivation
of p62dok results in sustained activation of Ras and MAPK
activity after removal of PDGF in p62dok/ MEF cells (10).
To ultimately prove that p62dok is responsible for the above
effects, we reintroduced p62dok into p62dok/ MEF cells
and examined whether the increased cell proliferation and
prolonged MAPK activity observed in these cells is re-
versed. Selected cell populations stably expressing p62dok or
empty vector were assessed for [3H]thymidine incorpora-
tion in response to PDGF. As shown in Fig. 1 A, reintro-
duction of p62dok diminished the enhanced proliferation
rate of p62dok/ MEF cells, whereas the empty vector had
no effect. To measure MAPK activity, total protein extracts
were prepared from cells at the indicated time points, and
subjected to Western blot analysis with anti-phospho-p44/
p42 MAPK (ERK1/2) Abs. While the duration of MAPK
activation was prolonged in p62dok/ MEF cells expressing
the empty vector, similar MAPK profiles were observed for
WT cells and p62dok/ MEF cells expressing p62dok (Fig. 1
B). We also examined the effects of p62dok overexpression
on PDGF-triggered MAPK activation using Rat1 stable cell
lines expressing empty vector or WT p62dok. Expression of
p62dok, but not empty vector, in Rat1 cells resulted in a re-
duction in phosphorylation of MAPK after 10 and 20 min
of PDGF stimulation (Fig. 1 C). Together, these results
confirm that p62dok is a negative regulator of PDGF-trig-
gered cell proliferation and MAPK activation.
In contrast to WT p62dok, the introduction of a mutant
p62dok lacking the PH domain, p62dokPH, into p62dok/
MEF cells did not suppress the sustained MAPK activity af-
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ter PDGF removal (Fig. 1 B). This result was confirmed in
Rat1 stable cell lines: overexpression of p62dokPH did not
reduce phosphorylation of MAPK after PDGF stimulation
(Fig. 1 C). These observations, together with the fact that
PH domains have previously been demonstrated to mediate
protein–membrane interactions, suggest that plasma mem-
brane recruitment of p62dok is essential for its negative ef-
fect on PDGF-triggered MAPK activation. However, the
membrane association of p62dok in response to growth fac-
tors and the function of its PH domain has until now not
been addressed.
The PH Domain Is Essential for PDGF-triggered Transloca-
tion of p62dok to the Plasma Membrane. To demonstrate that
the PH domain of p62dok is important for its subcellular lo-
calization, we initiated experiments examining its localiza-
tion in response to PDGF. We performed fractionation ex-
periments and examined the distribution of p62dok within
single living cells. For the fractionation experiments, we
used stable Rat1 fibroblast cell lines expressing WT p62dok
or p62dok lacking the PH domain (p62dokPH). These cells
were serum starved for 16 h, subsequently treated with
PDGF (50 ng/ml) for 15 min, and subjected to classical
subcellular fractionation techniques (see Materials and
Methods). For the detection of p62dok and p62dokPH,
equal amounts of protein of the supernatant (S100) and pel-
let (P100) fractions were subjected to immunoprecipitation
using polyclonal Abs raised against the COOH terminus of
p62dok followed by Western blotting using anti-p62dok
monoclonal Abs. In the absence of PDGF, more p62dok
protein can be detected in the S100 fraction than in the
P100 fraction. Upon PDGF stimulation, a major shift of the
protein to the P100 fraction can be observed, suggesting
that PDGF can trigger the relocalization of p62dok from the
cytoplasm to the membrane (Fig. 2). Furthermore, when
the same Western blot was stripped and probed with the
anti-phosphotyrosine Ab, PY20, a larger pool of phos-
Figure 1. Effects of p62dok on
cell proliferation and MAPK activ-
ity. (A) Proliferative response, de-
termined as [3H]thymidine incor-
poration of WT MEF  vector
(white bars); p62dok/ MEF 
vector (black bars); p62dok/ MEF 
p62dok (gray bars) with or without
PDGF treatment. (B) WT MEF
cells  vector and p62dok/ MEF
cells  p62dokWT;  p62dok
PH;  vector;  p62dokGBD
were stimulated with 50 ng/ml
PDGF for 10 min, then washed twice
and incubated in serum-free me-
dium for additional 15 and 30 min.
Cells at indicated time points were
lysed and subjected to Western blot (WB) analysis using polyclonal Abs against phospho-p44/42 MAPK. Abs against p42 MAPK were used to show ap-
proximately the same loading of proteins in all lanes, and monoclonal Abs against p62dok were used to show expression of the p62dok construct. (C) Rat1
cells expressing either empty vector; p62dok WT; p62dokPH or p62dokGBD were stimulated with PDGF (50 ng/ml) for 10 and 20 min. Lysates were
subjected to Western blot analysis and analyzed for MAPK activity as described in B. All figures are representative of experiments repeated three times.
(D) Rat1 cells were transiently transfected with empty vector, myc/His-tagged p62dokWT or myc/His-tagged p62dokGBD constructs, and stimulated
with PDGF (50 ng/ml) for 10 min. Total protein extracts were immunoprecipitated with Abs against Myc and subjected to Western blot analysis using
Abs against RasGAP and Nck (Transduction Laboratories).
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phorylated p62dok was found in the P100 fraction of PDGF-
treated cells when compared with unstimulated cells (Fig.
2). This suggest that p62dok undergoes further phosphoryla-
tion once recruited to the plasma membrane. The same re-
sults were obtained by directly performing Western blot
analysis on the S100 and P100 fractions, rather than first im-
munoprecipitating p62dok. Moreover, similar results were
obtained when PDGF-treated and -untreated p62dok/
MEF cells expressing p62dokWT were used in our frac-
tionation experiments (data not shown). In contrast,
p62dokPH was detected exclusively in the S100 fraction,
and remained unphosphorylated regardless of PDGF stimu-
lation (Fig. 2). Surprisingly, although a basal level of ty-
rosine phosphorylation can be seen for WT p62dok in the
cytosolic fraction of untreated cells, this is not the case for
p62dokPH. One possible explanation is that the PH do-
main itself contains a putative tyrosine phosphorylation site
and that this site is responsible for the basal level of phos-
phorylation noted for full-length p62dok.
To further confirm that PDGF stimulates relocalization
of p62dok to the plasma membrane, we expressed enhanced
green fluorescent protein (EGFP) fusion proteins of either
WT p62dok, the PH domain, or p62dok lacking the PH do-
main in Rat1 cells. These cells were transiently trans-
fected with one of the following GFP-fusion constructs:
p62dokWT-GFP, p62dokPH-GFP, p62dokPH-GFP, or
GFP alone. Cells were plated onto coverslips, serum
starved for 20 h, and stimulated with 50 ng/ml PDGF. Im-
ages were collected every 5 min over a period of 20 min
using confocal microscopy. The data in Fig. 3 show repre-
sentative examples of the distribution of p62dokWT-GFP,
p62dokPH-GFP, p62dokPH-GFP, and GFP alone before
and 10 min after PDGF stimulation. The localization of
p62dokWT-GFP and p62dokPH-GFP in unstimulated Rat1
fibroblasts was mainly cytosolic. A rapid translocation of
p62dokWT-GFP and p62dokPH-GFP to the plasma mem-
brane was observed upon treatment with PDGF (Fig. 3).
Both fusion proteins could be detected at the plasma mem-
brane 5 min after PDGF stimulation. In contrast, no plasma
membrane association of p62dokPH-GFP and GFP was
observed despite PDGF treatment (Fig. 3).
Together, these results indicate that the PH domain of
p62dok is essential to translocate the protein from the cyto-
Figure 2. Subcellular localization of p62dok. Rat1 cells expressing
p62dokWT or p62dokPH were treated as indicated; S100 (S) and P100
(P) fractions were separated by high-speed centrifugation. Equal
amount of proteins of both fractions were immunoprecipitated, using
Abs raised against the COOH terminus of p62dok, subjected to SDS/
PAGE and immunoblotted with mAb against p62dok ( p62dok) and
with mAb PY20 ( pTyr). Abs against PDGFR were used to demon-
strate the enrichment of this receptor in the membrane fraction and its
exclusion from the cytosolic fraction. All figures are representative of
experiments repeated four times.
Figure 3. PDGF-induced plasma membrane translocation of p62dok within single living cells. Rat1 cells expressing p62dokWT, p62dokPH-GFP,
p62dokPH-GFP, or empty GFP vector were stimulated with 50 ng/ml PDGF after serum starvation. Confocal images taken before and 10 min after
PDGF treatment are shown. A translocation to ruffle-like membrane structures can be noted for p62dokWT-GFP and p62dokPH-GFP, but not for
p62dokPH-GFP after PDGF treatment. GFP alone as well as the p62dokPH-GFP give nuclear staining, due to their smaller size. All figures are represen-
tative of experiments repeated three times.
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plasm to the plasma membrane in response to PDGF,
where it undergoes further phosphorylation by certain ki-
nase(s) in the vicinity.
Selective Binding of the PH Domain of p62dok to Phosphoino-
sitides In Vitro. To demonstrate that the PH domain of
p62dok binds to phospholipids in the plasma membrane, we
performed an in vitro assay using MLVs (28, 29). MLVs are
composed of a stack of lipid bilayers encapsulating an aque-
ous core, and represent a good model for the supramolecu-
lar organization of the lipids within the single bilayer of the
plasma membrane. MLVs can be collected out of suspen-
sion by centrifugation, and hence this allows us to study the
partitioning of a protein between the aqueous and the lipid
phase by analyzing the contents of the supernatant and the
lipid pellet. Recombinant His-tagged full-length p62dok,
p62dokPH, and p62dokPH proteins were purified as de-
scribed in Materials and Methods. We prepared MLVs
from either phosphatidylcholine (PC), PC and phosphati-
dylserine (PC/PS 70/30 mole percent), or a mixture of PC
and PS with one of the following phosphoinositides: Ptd-
Ins, PtdIns-3,4-P2, PtdIns-4,5-P2, or PtdIns-3,4,5-P3
(PC/PS/phosphoinositide 70/27/3 mole percent). It is
noteworthy that the latter indicated percentage of lipid
composition is close to that found in the plasma membrane.
MLVs were incubated with recombinant proteins, and
binding of the proteins to the lipids was detected by West-
ern blot analysis using Abs generated against N- and
COOH-terminal regions of p62dok.
Fig. 4 shows that in contrast to p62dokPH, which did
not bind to any of the MLVs prepared, full-length p62dok
and p62dokPH bound to MLVs containing PtdIns-3,4-P2,
PtdIns-4,5-P2, or PtdIns-3,4,5-P3. However, we did not
detect any binding of p62dok or p62dokPH to MLVs only
consisting of PC or PC/PS, indicating that the presence of
phosphoinositides is required for binding. Furthermore,
among the phosphoinositides tested, p62dok and p62dokPH
did not bind to PtdIns, indicating a preference for highly
phosphorylated phosphoinositides, such as PtdIns-3,4-P2,
PtdIns-4,5-P2, and PtdIns-3,4,5-P3. These results indicate
that the PH domain of p62dok is sufficient and necessary for
binding of p62dok to polyphosphoinositides.
Membrane Targeting of p62dok Is Dependent on PI3-Kinase
Activity In Vivo. Several lines of evidence support the no-
tion that agonist-triggered membrane recruitment of PH
domain–containing proteins is directed by binding of their
PH domains to lipid products of activated PI3-kinases (30–
32). Numerous growth factors, including PDGF, have
been shown to activate members of the PI3-kinase family
(33). Once activated, these lipid kinases are capable of
modifying position 3 of the inositol ring of phospholipids
with a phosphate group, so that four different lipid prod-
ucts can be generated, including PtdIns-3-P, PtdIns-3,4-P2,
PtdIns-3,5-P2, and PtdIns-3,4,5-P3. Among these products,
PtdIns-3,4-P2 and PtdIns-3,4,5-P3 have been demonstrated
to serve as targets for PH domains in cells (31, 33, 34).
Based on our findings, we hypothesized that PDGF-trig-
gered translocation of p62dok to the plasma membrane is
regulated by binding of its PH domain to products of PI3-
kinase. Hence, we performed in vivo experiments to estab-
lish whether the membrane translocation of p62dok is de-
pendent on PI3-kinase activation.
We initially assessed whether inhibitors of PI3-kinase
can interfere with the translocation of p62dok to the mem-
brane. Firstly, we performed fractionation experiments in
which we treated Rat1 cells stably expressing p62dok
with the specific PI3-kinase inhibitors, wortmannin or
LY292004 (35), before stimulating them with PDGF. As
shown in Fig. 5, addition of 25 nM wortmannin inhibited
the PDGF-triggered shift of the p62dok protein from the
S100 fraction to the P100 fraction. As a result, less tyrosine
phosphorylated p62dok protein is detected in the P100 frac-
tion, when compared with cells not treated with wortman-
nin. Similar results were obtained when 25 M LY292004
Figure 4. The PH domain of p62dok is necessary and sufficient for bind-
ing to polyphosphoinositides. MLVs were prepared from PC, PC/PS (70/
30 mole percent), or PC/PS/phosphoinositide (70/27/3 mole percent),
and lipids at a nominal total concentration of 200 ng/l were incubated
with 5 ng/l each of p62dokWT, the PH domain of p62dok, or p62dokPH
purified proteins. The aqueous and the lipid phases were separated by cen-
trifugation and the proteins in the supernatant and associated with the pellet
were detected by Western blotting. p62dok can bind through its PH domain
to lipid products generated by PI3-kinase, as well as to PtdIns-4,5-P2. The
results shown are representative of experiments performed with five inde-
pendent vesicle preparations and two protein batches.
Figure 5. Inhibition of PI3-kinase activity prevents PDGF-triggered
plasma membrane translocation of p62dok. Rat1 cells stably expressing
p62dok were pretreated with 25 nM wortmannin for 5 min before stimu-
lation with PDGF (50 ng/ml) for 15 min. S100 (S) and P100 (P) fractions
were separated by high-speed centrifugation. Equal amount of proteins of
both fractions were immunoprecipitated, using Abs raised against the
COOH terminus of p62dok, subjected to SDS/PAGE, and immunoblot-
ted with mAb p62dok ( p62dok) and with mAb PY20 ( pTyr). Abs
against PDGFR were used to demonstrate the enrichment of this recep-
tor in the membrane fraction and its exclusion from the cytosolic fraction.
All figures are representative of experiments repeated four times.
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was added (data not shown). Second, we examined the dis-
tribution of p62dokPH-GFP within single living cells as de-
scribed above. We observed that addition of 25 M
LY292004 to PDGF-pretreated p62dokPH-GFP expressing
cells caused an almost complete release of fluorescence
from the plasma membrane to the cytosol. As shown in
Fig. 6 A, after 10 min incubation with the drug, p62dokPH-
GFP was barely detectable at the plasma membrane.
We also investigated whether expression of an activated
mutant form of PI3-kinase is sufficient to trigger the translo-
cation of the PH domain of p62dok to the membrane. We
cotransfected a membrane-targeted form of p110 PI3-
kinase (PI3K-CAAX) and p62dokPH-GFP into Rat1 cells.
Expression of this PI3-kinase mutant construct was previ-
ously shown to cause the production of PtdIns-3,4,5-P3 and
PtdIns-3,4-P2, and to induce the formation of lamellipodia
and membrane ruffles (36, 37). We noted that expression of
PI3K-CAAX drives the recruitment of p62dokPH-GFP (but
not of p62dokPH-GFP) to the plasma membrane in serum-
starved Rat1 cells (Fig. 6 B), indicating that alterations in
lipid composition caused by activated PI3-kinase result in
binding of the PH domain of p62dok to the plasma membrane
in vivo. In contrast, p62dokPH-GFP was not observed at the
plasma membrane in serum-starved cells when cotransfected
with the empty vector. Thus, our in vivo experiments indi-
cate that the PH domain–mediated plasma membrane trans-
location of p62dok is dependent on PI3-kinase activation.
The Negative Effect of p62dok on PDGF-triggered MAPK Ac-
tivation Is Independent of RasGAP and Nck Association. We
have provided considerable evidence that the plasma mem-
brane recruitment of p62dok is essential for its function.
However, once at the membrane, the signaling components
through which p62dok negatively influences PDGF-elicited
MAPK activity have not been well defined. One potential
candidate is RasGAP, previously shown to associate with
phosphorylated p62dok (1, 4, 8, 13, 16). A plausible mecha-
nism is that, upon PDGF stimulation, p62dok brings RasGAP
into the vicinity of Ras at the plasma membrane, thus accel-
erating the hydrolysis of RasGTP to RasGDP, and in turn
decreasing MAPK activity. To address this possibility, we
took advantage of the previously mapped RasGAP binding
sites on p62dok to generate a mutant deficient in RasGAP
binding (p62dokGBD), in which Tyr-296, 315, 362, 398, and
409 have been mutated into phenylalanines (38). We con-
firmed that this mutant fails to interact with RasGAP in
PDGF-treated Rat1 cells (Fig. 1 D). Subsequently, we intro-
duced p62dokGBD into p62dok/ MEF cells or Rat1 cells to
assess whether it can suppress PDGF-elicited MAPK activity.
As shown in Fig. 1 B, this mutant could still diminish the
prolonged MAPK activity seen in p62dok/ cells after the
Figure 6. PI3-kinase depen-
dent recruitment of p62dokPH-
GFP to the plasma membrane. (A)
Effects of the PI3-kinase inhibi-
tors on the localization of
p62dokPH-GFP in PDGF-pre-
treated Rat1 cells. Rat1 cells were
transfected with p62dokPH-GFP
and treated with PDGF (50 ng/ml)
for 10 min. Addition of 25 M
LY292004 reversed plasma mem-
brane translocation. (B) Effects of
membrane-targeted PI3-kinase on
the localization of p62dokPH-GFP
and p62dokPH-GFP. Rat1 cells
were cotransfected with a mem-
brane-targeted version of PI3-
kinase (PI3K-CAAX) and
p62dokPH-GFP or p62dokPH-
GFP and serum starved. Expres-
sion of PI3K-CAAX triggers the
recruitment of p62dokPH-GFP, but
not of p62dokPH-GFP, to the
membrane. All figures are repre-
sentative of experiments repeated
three times.
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removal of PDGF. Moreover, overexpression of p62dokGBD
in Rat1 cells was also able to decrease PDGF-triggered
MAPK activity (Fig. 1 C). These results suggest that associa-
tion of p62dok with RasGAP is not essential for its negative
effect on the PDGF-triggered MAPK activation. Further-
more, Noguchi et al. have previously shown that Tyr 361 in
mouse p62dok is indispensable for its interaction with Nck
(16). The phenylalanine substitution of its human counter-
part, Tyr362, which is contained in the p62dokGBD mutant,
also abolished the binding to Nck (Fig. 1 D). The latter im-
plies that p62dok also does not exert its effect through its in-
teraction with Nck. Further identification and characteriza-
tion of p62dok-interacting proteins will be required to define
the precise mechanism by which p62dok negatively influences
the PDGFR/Ras/MAPK signaling pathway.
Discussion
A central route by which growth factors, such as PDGF,
regulate cell proliferation is via the receptor tyrosine kinase
(PDGFR), Ras, and MAPK signaling cascade, the disregu-
lation of which has been implicated in numerous cancers
(39, 40). The output of this pathway is tightly controlled by
both positive and negative regulators. Although the adaptor
proteins identified to date mainly function as positive regu-
lators of RTK signaling (12), we have demonstrated that the
RasGAP-associated docking protein, p62dok, acts as a nega-
tive regulator of the PDGFR/Ras/MAPK signaling path-
way. Through the reintroduction of p62dok into p62dok/
MEF cells, we were able to suppress the increase in MAPK
activity and cell proliferation observed in these cells, hence
unequivocally showing that p62dok does indeed negatively
affect MAPK signaling initiated by RTKs. We further dem-
onstrated that translocation of p62dok to the plasma mem-
brane in response to PDGF is mediated through its PH do-
main and regulated by PI3-kinase activity, and that this
event is essential for its role as a negative regulator. Further-
more, we showed that the inhibition of MAPK activity is
independent of RasGAP and Nck binding to p62dok.
Plasma membrane targeting of proteins is often accom-
plished via protein-lipid and/or protein–protein interac-
tions, which can be mediated by PH and PTB domains
(31). PH domains are generally involved in phosphoinosi-
tide binding, as in the case of Btk (32), while PTB domains
interact with phosphotyrosines on plasma membrane–asso-
ciated receptors, as in the case of Shc (30). As mentioned
above, Dok family members contain an N-terminal PH
domain followed by a PTB domain. The presence of these
domains strongly implies that these adaptors function at the
inner surface of the plasma membrane. We have demon-
strated that in response to PDGF, p62dok translocates to the
plasma membrane where it can become further phosphory-
lated. In contrast, p62dok lacking the PH domain is insensi-
tive to PDGF treatment, as it remains cytosolic and is un-
phosphorylated. Furthermore, upon PDGF stimulation, the
PH domain alone of p62dok was able to associate with the
plasma membrane, as well as interact with phosphoinosi-
tides directly in vitro. Taken together, these data support
the idea that the PH domain of p62dok is crucial to anchor
the protein to the plasma membrane in order to propagate
signaling events initiated by RTKs. In support of this idea,
Noguchi et al. showed that the PH domain is essential for
insulin-triggered phosphorylation of p62dok and for its ef-
fect on cell migration (16). In contrast to our findings
above, Tamir et al. suggest that membrane recruitment of
p62dok requires the aid of additional molecules. They found
that p62dok is phosphorylated during FcRIIB activation in
WT B cells, but not in cells lacking SHIP1. Based on this
observation, and that p62dok can interact with SHIP-1 via
its PTB domain, the authors proposed that p62dok is re-
cruited to the vicinity of the plasma membrane by SHIP1,
which is able to associate with FcRIIB upon receptor ac-
tivation (8). As SHIP1 is exclusively expressed in hemato-
poietic cells, and FcRIIB belongs to the family of antigen
receptors, we conclude that this contradiction is likely to
be due to differences in cell and receptor types. Subcellular
localization studies of p62dok in B cells will be required to
further address this issue. With regard to other Dok family
members, abrogation of the phosphorylation of p56dok-2 in
response to EGF required the mutation of two highly con-
served arginines in the PTB domain in addition to the de-
letion of the PH domain. This implies that interaction of
the PTB domain of p56dok-2 with a phosphotyrosine within
the receptor is required for its localization at the plasma
membrane (23). Although Dok proteins share aa sequence
similarity and generally behave as negative regulators in
cellular signaling, divergence between the Dok family
members exist. For example, the different Dok family
members have different COOH-terminal sequences, dif-
ferent expression patterns, and are phosphorylated by dif-
ferent receptors. Hence, the mechanism by which different
Dok family members negatively regulate signaling cascades
important for the control of cell proliferation may involve
common, as well as distinct events.
In general, agonist-triggered recruitment of PH domain-
containing proteins to the plasma membrane involves acti-
vation of PI3-kinase, which results in the production of Ptd-
Ins-3,4-P2 and/or PtdIns-3,4,5-P3, to which PH domains
of the host proteins target and bind (30–32). We have
found that the PH domain of p62dok is a target of PI3-kinase
lipid products. Using an in vitro MLV lipid binding assay,
we have shown that the PH domain of p62dok preferentially
bound to polyphosphoinositides, including PI3-kinase gen-
erated phosphoinositides, PtdIns-3,4-P2, PtdIns-3,4,5-P3, as
well as a non–PI3-kinase generated phosphoinositide, Ptd-
Ins-4,5-P2. Given that PI3-kinase products are less abun-
dant in the cell than PtdIns-4,5-P2, even after agonist treat-
ment (31), one would expect that the PH domain of p62dok
would bind more strongly to PI3-kinase products than to
PtdIns-4,5-P2 in vivo, if the former lipid products can tar-
get the PH domain to the plasma membrane. However, we
must keep in mind that the above assay is an in vitro assay,
and that either posttranslational modifications, such as tyro-
sine phosphorylation, or other factors normally present in
vivo may restrict the specificities even further. To address
the significance of the binding of p62dok to PI3K products
 o
n
 D
ecem
ber 18, 2013
jem.rupress.org
D
ow
nloaded from
 
Published July 30, 2001
273 Zhao et al.
in vivo, we used a p62dokPH-GFP construct which we in-
troduced into Rat1 cells. Our data showed that unlike the
PH domain of PLC (32), the PH domain of p62dok does
not localize at the plasma membrane in serum-starved cells.
This suggests that it does not have a high enough affinity in
vivo to interact with PtdIns-4,5-P2. We also found that the
addition of pharmacological inhibitors of PI3-kinase inter-
fered with the PDGF-triggered localization of p62dok at the
membrane. Furthermore, expression of an activated mutant
form of PI3-kinase is sufficient to localize p62dokPH-GFP
to the plasma membrane. Thus, these in vivo results indi-
cate that targeting of p62dok to the plasma membrane via its
PH domain is regulated by PI3-kinase activity in cells.
As an adaptor protein which translocates to the plasma
membrane upon PDGF stimulation, it is reasonable to sup-
pose that p62dok aids in the formation of a multiple protein
signaling complex at the membrane. Consequently, pro-
teins in this complex would play key roles in regulating
cellular signaling initiated by the PDGFR. We found that
p62dok lacking the PH domain was not able to suppress
MAPK activity when reintroduced into p62dok/ MEF
cells, or when overexpressed in Rat1 cells. This observa-
tion strongly supports a model in which p62dok is regulated
by translocation to the plasma membrane via its PH do-
main in order to negatively affect the MAPK pathway. In
principle, p62dok may exert its negative effect on the Ras/
MAPK pathway by either recruiting negative regulators of
the pathway, or by sequestering and inactivating positive
regulators. Given these possibilities and known p62dok-
interacting proteins, three models are plausible. (a) p62dok
links RasGAP to attenuation of Ras signaling. As previ-
ously mentioned, the functional significance of the associa-
tion of p62dok with RasGAP is inconclusive (8, 22, 23). We
therefore examined the effects of a p62dok mutant deficient
in RasGAP binding, and found that this mutant was still
capable of suppressing PDGF-induced MAPK activity in
p62dok/ MEF cells, as well as in Rat1 cells. Thus, our
data suggest that p62dok is not dependent on its association
with RasGAP to exert its negative effect on MAPK activ-
ity. (b) p62dok may act in conjunction with a negative regu-
lator other than RasGAP. Lemay et al. showed that inter-
actions between Dok3 and inhibitory molecules, such as
Csk and SHIP1, are important for the negative effect of
Dok3 on BCR-triggered cytokine production, which ac-
tually does not involve MAPK activation (21). SHIP1 and
Csk have been shown to interact with tyrosine-phosphory-
lated p62dok (8, 13, 17). We can exclude SHIP1 as a possi-
ble candidate, given that its expression is restricted to he-
matopoietic cell lines (41). The involvement of Csk is
unclear and awaits the identification of its binding sites on
p62dok. However, data by Songyang et al. indicate that Csk
is not involved in mediating the negative effect of p62dok
on Src-induced transformation (14). (c) p62dok may inter-
fere with the recruitment of positive mediators of Ras sig-
naling, such as Nck and Shc, to activated receptors. Both
Nck and Shc have been identified in a protein complex
which coimmunprecipitates with p62dok (13, 15, 16). We
excluded the possibility of Nck sequestration by using the
above p62dokGBD mutant which is also incapable of bind-
ing to Nck. However, sequestration of Shc by p62dok re-
mains a possibility, but has not yet been defined. Identifica-
tion of additional p62dok-interacting proteins will provide
us with a more comprehensive view as to how p62dok
achieves its negative effect on cellular signaling.
In conclusion, our studies provide insights into the mo-
lecular mechanism by which p62dok negatively regulates the
RTK/MAPK signaling pathway. We have found that the
PH domain–mediated translocation of p62dok to the plasma
membrane occurs in a PI3-kinase activity–dependent man-
ner, and is necessary for the effects of p62dok in RTK sig-
naling. Given that p62dok acts downstream of multiple tyro-
sine kinases, including oncogenic kinases, unraveling the
mechanism by which p62dok regulates RTK signaling path-
ways will help us to understand its role in cell growth con-
trol, as well as oncogenic transformation.
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